Featured studies include only those currently recruiting participants. They are listed according to the date they were added to the ClinicalTrials.gov registry, with the most recent studies appearing first.
- Spatial Context and Fear Learning.
Evaluation study. Background: - Fear is a normal response to a threat. Ages 18-50. Location in Bethesda, MD.
- PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX.
Evaluation study. Objective: Metabotropic glutamate receptors (mGluRs) are G-protein coupled receptors that respond to glutamate by activating proteins inside nerve cells that affect cell metabolism, thereby fine-tuning the signals sent between cells to maintain balance in neuronal activity. Ages 18-55. Location in Bethesda, MD.
- Cognitive vs. Emotional Psychopharmacological Manipulations of Fear vs. Anxiety.
Interventional study. Background: Stress and anxiety can interfere with how well people perform tasks. Ages 18-50. Location in Bethesda, MD.
- A Pilot Study to Extend the K-SADS-PL to Adolescents and Young Adults.
Evaluation study. Background: - An interview called the Schedule for Affective Disorders and Schizophrenia for School Age Children Present and Lifetime version (K-SADS-PL) is used to identify mental health problems among children and younger teens. Ages 18-80. Location in Bethesda, MD.
- Anxiety and Recurrent Abdominal Pain in Children.
Interventional study. This study aims to determine whether citalopram is a useful, well-tolerated, and safe treatment for children and adolescents ages 7 to 18 years with functional abdominal pain. Ages 7-18. Location in Columbus, OH.
- Preventing Anxiety Disorders in Youth.
Interventional study. This study will determine the effectiveness of a cognitive behavioral therapy program in preventing anxiety disorders in at-risk children. Ages 8-12. Location in Baltimore, MD.
- Child and Adolescent Anxiety Disorders (CAMS).
Interventional study. This 9-month study will compare the effectiveness of the medication sertraline (Zoloft®), cognitive-behavioral therapy, the combination of these treatments, and placebo for youth with anxiety disorders. Ages 7-17.